A report from research firm Decision Resources predicts no growth in the asthma drug market through 2020, in large part due to incursions by generics and greater competition. According to the company, “The overall asthma drug market will decrease slightly from $14.6 billion in 2010 to $14.4 billion in 2020 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.”
Analyst Amanda Puffer said, “Despite the dramatic annual decline in sales of Singulair, emerging agents that offer the convenience of once-daily dosing will generate over $2.3 billion in sales in 2020 at the expense of market leaders that are dosed twice daily. Driving these sales will be the uptake of emerging once-daily LABA/ICS combinations, including GlaxoSmithKline/Theravance’s Relovair, and these gains will serve to offset the decline in sales due in part to the entry of generic Singulair.”
The report also suggests that successful launches new anticytokine agents will “begin to fulfill an important unmet need for difficult-to-control patients and their launch signifies a move toward personalized medicine for the treatment of asthma.”
Read the Decision Resources press release.
